Volitinib demonstrated robust in vivo anti-tumor effects on predominantly MET-driven gastric and lung cancers in which the MET gene was amplified, while volitinib combined with chemotherapy could produce additional benefits in the treatment of tumors in which MET was a partial driver and where patients exhibited poor responses to volitinib monotherapy [68–71]. Here, MET is linked to lung cancer.